How I treat MDS after hypomethylating agent failure

Area of Science:

• Hematology and Oncology
• Molecular Biology
• Clinical Therapeutics

Background:

• Hypomethylating agents (azacitidine, decitabine) are standard treatments for myelodysplastic syndrome (MDS).
• Approximately 50% of patients respond to HMAs, but responses are often transient.
• Limited approved treatment options exist for patients who fail HMA therapy.

Observation:

• Predicting HMA response is possible using clinical and molecular factors.
• Failure to respond to HMAs necessitates a strategic approach to subsequent therapy.
• Reassessing molecular and cytogenetic profiles at HMA failure is vital for treatment decisions.

Findings:

• Therapeutic choices post-HMA failure should consider resistance type (primary vs. secondary) and disease progression.
• Stem cell transplantation and chemotherapy are potential rescue strategies but are feasible for a minority of patients.
• Novel agents targeting specific molecular alterations (e.g., IDH2, spliceosome mutations) and pathways (e.g., BCL2 inhibitors) show promise.

Implications:

• Developing reasoned therapeutic strategies after HMA failure is critical for improving patient outcomes in MDS.
• Clinical trial enrollment for patients experiencing HMA failure is essential for advancing treatment options.
• Targeted therapies hold significant potential for managing MDS in the context of HMA resistance.